Nan Nan Lu

lnn279@ustc.edu.cn

Chinese, English

Anhui

University of Science and Technology of China

Mayo Clinic College of Medicine

• PhD in Oncology: University of Science and Technology of China
• Postdoctoral Research: University of Science and Technology of China
• Visiting Scholar: Mary Washington Hospital, USA
• Published over 30 academic papers in renowned journals

• 2024.06-present - University of Science and Technology of China, First Affiliated Hospital - Director of Breast Tumor Internal Medicine Subspecialty
• 2024.01-present - University of Science and Technology of China, First Affiliated Hospital - Chief Physician
• 2019.09-2023.09 - University of Science and Technology of China - Postdoctoral Researcher in Biology
• 2019.01-2023.12 - University of Science and Technology of China, First Affiliated Hospital - Associate Chief Physician
• 2018.03-2018.06 - Mary Washington Hospital, USA - Visiting Scholar
• 2016.01-2018.12 - University of Science and Technology of China, First Affiliated Hospital - Attending Physician
• 2012.07-2015.12 - Anhui Provincial Hospital - Physician

• Anhui Province First Health and Wellness 'Key Talent' (2022): Provincial Level
• Third 'Outstanding Young and Middle-aged Talent' (2023): Hospital Level
• Best Contribution Individual Award (2022): Hospital Level
• Excellent Doctoral Award (2019): Hospital Level
• Single Outstanding Paper Award (2018): Hospital Level

Construction and anti-tumor mechanism of malignant tumor microenvironment-responsive nano-drug delivery systems
Observational and translational research on breast tumors
Clinical application of new in-situ vaccine therapy technologies for advanced breast tumors
Application of anti-tumor small molecule targeted drug concentration monitoring in clinical treatment
Role of AI big data analysis in clinical and basic research of malignant tumors

• Development of a Multiparametric Model for Predicting the Response to Neoadjuvant Chemotherapy in Breast Cancer, F. Qian, Y. Mao, J. Dong, F. Xie, X. Fang, Q. Zhang, P. Xia, X. Han*, N. Lu*, 2024
• Immune Microenvironment and Clinical Feature Analyses Based on a Prognostic Model in Lymph Node-positive Breast Cancer, N. Lu#, C. Fu#, L. Zhang, Y. You, X. Li, Q. Zhang, P. Wang*, X. Han*, 2023
• Acid-Responsive Endosomolytic Polymeric Nanoparticles with Amplification of Intracellular Oxidative Stress for Prodrug Delivery and Activation, N. Lu, L. Xi, Z. Zha, Y. Wang, X. Han*, Z. Ge*, 2021
• Predicting Pathologic Response to Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer using Multiparametric MRI, N. Lu, J. Dong, X. Fang, L. Wang, W. Jia, Q. Zhou, L. Wang, J. Wei, Y. Pan, X. Han*, 2021
• Length effect of stimuli-responsive block copolymer prodrug filomicelles on drug delivery efficiency, W. Ke#, N. Lu#, A.A.-W.M.M. Japir, Q. Zhou, L. Xi, Y. Wang, D. Dutta, M. Zhou, Y. Pan, Z. Ge*, 2020
• Hypoxia-Responsive Polyprodrug Nanocarriers for Near Infrared Light-Boosted Photodynamic-Chemotherapy, D. Dutta, Q. Zhou, J. F. Mukerabigwi, N. Lu* (共同通讯作者), Z. Ge*, 2021
• Cisplatin Resistance Reversal of Lung Cancers by Tumor Acidity-Activable Vesicular Nanoreactors via Tumor Oxidative Stress Amplification, J.F. Mukerabigwi, Y. Han, N. Lu* (共同通讯作者), W. Ke, Y. Wang, Q. Zhou, F. Mohammed, A. Ibrahim, B. Zheng*, Z. Ge*, 2021
• Protein-Delivering Nanocomplexes with Fenton Reaction-Triggered Cargo Release to Boost Cancer Immunotherapy, X. Li, Q. Zhou, A.A.-W.M.M. Japir, D. Dutta, N. Lu, Z. Ge*, 2022
• Hypoxia-responsive block copolymer polyprodrugs for complementary photodynamic-chemotherapy, Q. Zhou, F. Mohammed, Y. Wang, J. Wang, N. Lu, J. Li*, Z. Ge*, 2021